Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

This Phase III trial tests whether the targeted drug olaparib (a PARP inhibitor) given after chemoradiation is more effective than observation alone in preventing recurrence in patients with a high-risk molecular subtype of endometrial (uterine) cancer called p53-abnormal. **You may be eligible if...** - You have histologically confirmed endometrial cancer (any grade; including endometrioid, serous, clear cell, undifferentiated, or uterine carcinosarcoma) - Your tumor has been classified as the p53-abnormal molecular subtype - You had surgery to remove the uterus (with or without lymph node removal) with no visible remaining cancer - You have no distant spread confirmed by imaging - You are 18 or older with a life expectancy of at least 16 weeks **You may NOT be eligible if...** - Distant metastases are found before or after surgery - Your tumor does not fall into the required molecular classification - You cannot receive the required chemoradiation Talk to your doctor to see if this trial is right for you.